Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3

Active, not recruiting

• Conditions: Endometrial Serous Adenocarcinoma; Recurrent Endometrial Carcinoma; Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Adenocarcinoma; Stage III Uterine Corpus Cancer AJCC v8; Endometrial Dedifferentiated Carcinoma; Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Dedifferentiated Carcinoma; Recurrent Endometrial Serous Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma
• Interventions: Drug: Carboplatin; Procedure: Computed Tomography; Drug: Paclitaxel; Other: Placebo Administration; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration

• Registration Number: NCT03914612
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the ...

Detailed Description

PRIMARY OBJECTIVE:

I. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.

SECONDARY OBJECTIVES:
...

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2019-04-12
• Study First Submitted QC: 2019-04-12
• Study First Posted: 2019-04-16
• Study Start: 2019-07-16
• Primary Completion: 2022-12-16
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-13
• Last Update Posted: 2023-05-16
• Study Completion: 2024-05-10

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Female
• Target Recruitment: 759

Inclusion Criteria

• Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.

• Pathology report showing results of institutional MMR IHC testing.

• Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.).

• Submission of tumor specimens for centralized MMR IHC testing is required after Step 1 and before Step 2 registration.

• In patients with measurable disease, lesions will be defined and monitored by RECIST version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.

• Patients may have received

  • NO prior chemotherapy for treatment of endometrial cancer OR
  • Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed >= 12 months prior to STEP 2 registration.

• Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to STEP 2 registration.

• Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to STEP 2 registration.

• Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted.

• Age >= 18

• Performance status of 0, 1 or 2.

• Platelets >= 100,000/mcl.

• Absolute neutrophil count (ANC) >= 1,500/mcl.

• Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN).

• Total serum bilirubin level =< 1.5 x upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled).

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN.

• Thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal Free T4 level is required.

• Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 2 registration are eligible for this trial.

• For patients of child bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.

• Administration of study drugs (pembrolizumab [MK-3475], paclitaxel, carboplatin) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from at least 14 days prior to Step 2 registration (for oral contraceptives), during treatment, and for 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:

  • Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
  • Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to Step 2 registration; OR
  • Have a congenital or acquired condition that prevents childbearing.

• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

• The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.

Read More

Exclusion Criteria

• Patients with prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.

• Patients who have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab (MK-3475) and/or its excipients; and/or a severe hypersensitivity reaction to paclitaxel and/or carboplatin

• Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 2 registration.

• Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Step 2 registration.

  • Patients who have received steroids as CT scan contrast premedication may be enrolled.
  • The use of inhaled or topical corticosteroids is allowed.
  • The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
  • The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.

• Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to Step 2 registration and remain clinically stable.

• Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease.

• Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.

• Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.

• Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.

• Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; and cirrhosis.

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

• Pregnant or lactating patients.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm I (placebo, paclitaxel, carboplatin)	Questionnaire Administration	COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions.
Arm I (placebo, paclitaxel, carboplatin)	Placebo Administration	COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions.
Arm II (pembrolizumab, paclitaxel, carboplatin)	Computed Tomography	COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study.
Arm II (pembrolizumab, paclitaxel, carboplatin)	Pembrolizumab	COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study.
Arm II (pembrolizumab, paclitaxel, carboplatin)	Quality-of-Life Assessment	COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study.
Arm II (pembrolizumab, paclitaxel, carboplatin)	Questionnaire Administration	COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study.
Arm I (placebo, paclitaxel, carboplatin)	Computed Tomography	COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions.
Arm I (placebo, paclitaxel, carboplatin)	Quality-of-Life Assessment	COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions.
Arm I (placebo, paclitaxel, carboplatin)	Carboplatin	COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions.
Arm I (placebo, paclitaxel, carboplatin)	Paclitaxel	COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions.
Arm II (pembrolizumab, paclitaxel, carboplatin)	Carboplatin	COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study.
Arm II (pembrolizumab, paclitaxel, carboplatin)	Paclitaxel	COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study.

Primary Outcome Measures

Name	Time	Method
Progression-free survival (PFS)	Duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years	Will be tested with a stratified log-rank statistic.

Secondary Outcome Measures

Name	Time	Method
Incidence of pembrolizumab treatment and self-reported neurotoxicity	5 years	Assessed with FACT/GOG-Ntx.
Overall survival (OS)	Time from study entry to time of death or the date of last contact, assessed up to 5 years
Objective tumor response	5 years	Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1.
Association between PD-L1 IHC and MMR status	5 years	Measures of association between PD-L1 IHC (CPS) and MMR IHC status. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient).
Duration of objective response	5 years	The time difference between the dates of first response and first progression; patients who do not progress are considered censored.
Effect of pembrolizumab on PFS and OS by Program Death Ligand 1 (PD-L1) IHC	5 years	Will assess the effect of pembrolizumab on PFS and OS by PD-L1 (combined positive score \[CPS\]) within proficient MMR (pMMR) and deficient MMR (dMMR) populations. The effectiveness of pembrolizumab will be compared by PD-L1 status (CPS). A formal test will be conducted by examining the interaction term between pembrolizumab treatment (yes or no) with PD-L1 ...
Incidence of adverse events	5 years	Assessed by Common Terminology Criteria for Adverse Events (CTCAE). Toxicities will be screened for differences between treatments by using an exact method or a Chi-Square test. For a given adverse event, each patient will be graded according to the worse grade experienced while on therapy (and within 30 days of treatment). These toxicities will then be divi...
Quality of life (QoL) and patient-reported outcomes (PROs)	5 years	Measured by the Function Assessment of Cancer Therapy (FACT)-Endometrial Trial Outcome Index (En-TOI), the FACT/Gynecologic Oncology Group (GOG)-Neurotoxicity (Ntx) subscale (short), Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue (short form),the PROMIS-physical function (short form) and a single-item measuring bother from side eff...
Concordance between Institutional Mismatch repair (MMR) immunohistochemistry (IHC) testing and centralized MMR IHC	5 years	Concordance between institutional MMR IHC testing and centralized MMR IHC. The patient's MMR IHC status will be assessed for prognostic value by conducting stratified log-rank tests or Cox Proportional Hazards (PH) modeling when assessing the impact on PFS or OS. When assessing the impact on the probability of response, a logistic regression model will be co...

Trial Locations

Locations (396)

NYP/Weill Cornell Medical Center; 🇺🇸 New York, New York, United States

Stony Brook University Medical Center; 🇺🇸 Stony Brook, New York, United States

Atrium Health Cabarrus/LCI-Concord; 🇺🇸 Concord, North Carolina, United States

Southeastern Medical Oncology Center-Clinton; 🇺🇸 Clinton, North Carolina, United States

Carolinas Medical Center/Levine Cancer Institute; 🇺🇸 Charlotte, North Carolina, United States

Southeastern Medical Oncology Center-Goldsboro; 🇺🇸 Goldsboro, North Carolina, United States

Novant Health New Hanover Regional Medical Center; 🇺🇸 Wilmington, North Carolina, United States

Margaret R Pardee Memorial Hospital; 🇺🇸 Hendersonville, North Carolina, United States

Sanford Roger Maris Cancer Center; 🇺🇸 Fargo, North Dakota, United States

Aultman Health Foundation; 🇺🇸 Canton, Ohio, United States

UHHS-Chagrin Highlands Medical Center; 🇺🇸 Beachwood, Ohio, United States

Miami Valley Hospital South; 🇺🇸 Centerville, Ohio, United States

UH Seidman Cancer Center at Saint John Medical Center; 🇺🇸 Westlake, Ohio, United States

Oklahoma Cancer Specialists and Research Institute-Tulsa; 🇺🇸 Tulsa, Oklahoma, United States

Legacy Meridian Park Hospital; 🇺🇸 Tualatin, Oregon, United States

Lehigh Valley Hospital - Muhlenberg; 🇺🇸 Bethlehem, Pennsylvania, United States

Adams Cancer Center; 🇺🇸 Gettysburg, Pennsylvania, United States

Cherry Tree Cancer Center; 🇺🇸 Hanover, Pennsylvania, United States

Geisinger Medical Center-Cancer Center Hazleton; 🇺🇸 Hazleton, Pennsylvania, United States

Jefferson Hospital; 🇺🇸 Jefferson Hills, Pennsylvania, United States

Kaiser Permanente Los Angeles Medical Center; 🇺🇸 Los Angeles, California, United States

Sechler Family Cancer Center; 🇺🇸 Lebanon, Pennsylvania, United States

Cancer Care Center of O'Fallon; 🇺🇸 O'Fallon, Illinois, United States

Johns Hopkins University/Sidney Kimmel Cancer Center; 🇺🇸 Baltimore, Maryland, United States

Forbes Hospital; 🇺🇸 Monroeville, Pennsylvania, United States

USC / Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

Thomas Jefferson University Hospital; 🇺🇸 Philadelphia, Pennsylvania, United States

Sinai Hospital of Baltimore; 🇺🇸 Baltimore, Maryland, United States

UPMC Hillman Cancer Center - Monroeville; 🇺🇸 Monroeville, Pennsylvania, United States

Reading Hospital; 🇺🇸 West Reading, Pennsylvania, United States

Geisinger Wyoming Valley/Henry Cancer Center; 🇺🇸 Wilkes-Barre, Pennsylvania, United States

WellSpan Health-York Cancer Center; 🇺🇸 York, Pennsylvania, United States

Women and Infants Hospital; 🇺🇸 Providence, Rhode Island, United States

WellSpan Health-York Hospital; 🇺🇸 York, Pennsylvania, United States

Sanford Cancer Center Oncology Clinic; 🇺🇸 Sioux Falls, South Dakota, United States

Avera Cancer Institute; 🇺🇸 Sioux Falls, South Dakota, United States

UT Southwestern/Simmons Cancer Center-Dallas; 🇺🇸 Dallas, Texas, United States

Parkland Memorial Hospital; 🇺🇸 Dallas, Texas, United States

Houston Methodist Sugar Land Hospital; 🇺🇸 Sugar Land, Texas, United States

University of Vermont Medical Center; 🇺🇸 Burlington, Vermont, United States

West Virginia University Charleston Division; 🇺🇸 Charleston, West Virginia, United States

Legacy Salmon Creek Hospital; 🇺🇸 Vancouver, Washington, United States

Monongalia Hospital; 🇺🇸 Morgantown, West Virginia, United States

Marshfield Medical Center-EC Cancer Center; 🇺🇸 Eau Claire, Wisconsin, United States

Aurora Cancer Care-Grafton; 🇺🇸 Grafton, Wisconsin, United States

Aurora Health Care Germantown Health Center; 🇺🇸 Germantown, Wisconsin, United States

Aurora Cancer Care-Kenosha South; 🇺🇸 Kenosha, Wisconsin, United States

Grady Health System; 🇺🇸 Atlanta, Georgia, United States

Aurora Bay Area Medical Group-Marinette; 🇺🇸 Marinette, Wisconsin, United States

Emory University Hospital/Winship Cancer Institute; 🇺🇸 Atlanta, Georgia, United States

Emory Saint Joseph's Hospital; 🇺🇸 Atlanta, Georgia, United States

Marshfield Medical Center-Marshfield; 🇺🇸 Marshfield, Wisconsin, United States

Riverside Methodist Hospital; 🇺🇸 Columbus, Ohio, United States

The Mark H Zangmeister Center; 🇺🇸 Columbus, Ohio, United States

ProHealth Oconomowoc Memorial Hospital; 🇺🇸 Oconomowoc, Wisconsin, United States

Vince Lombardi Cancer Clinic - Oshkosh; 🇺🇸 Oshkosh, Wisconsin, United States

Marshfield Medical Center-Rice Lake; 🇺🇸 Rice Lake, Wisconsin, United States

Marshfield Medical Center-River Region at Stevens Point; 🇺🇸 Stevens Point, Wisconsin, United States

Aurora Medical Center in Summit; 🇺🇸 Summit, Wisconsin, United States

Vince Lombardi Cancer Clinic-Two Rivers; 🇺🇸 Two Rivers, Wisconsin, United States

UW Cancer Center at ProHealth Care; 🇺🇸 Waukesha, Wisconsin, United States

Aurora Cancer Care-Milwaukee West; 🇺🇸 Wauwatosa, Wisconsin, United States

Aurora West Allis Medical Center; 🇺🇸 West Allis, Wisconsin, United States

Marshfield Medical Center - Weston; 🇺🇸 Weston, Wisconsin, United States

The Moncton Hospital; 🇨🇦 Moncton, New Brunswick, Canada

Royal Victoria Regional Health Centre; 🇨🇦 Barrie, Ontario, Canada

Juravinski Cancer Centre at Hamilton Health Sciences; 🇨🇦 Hamilton, Ontario, Canada

Kingston Health Sciences Centre; 🇨🇦 Kingston, Ontario, Canada

London Regional Cancer Program; 🇨🇦 London, Ontario, Canada

Lakeridge Health Oshawa; 🇨🇦 Oshawa, Ontario, Canada

University Health Network-Princess Margaret Hospital; 🇨🇦 Toronto, Ontario, Canada

Algoma District Cancer Program Sault Area Hospital; 🇨🇦 Sault Ste Marie, Ontario, Canada

Health Sciences North; 🇨🇦 Sudbury, Ontario, Canada

Hopital de la Cite-de-la-Sante; 🇨🇦 Laval, Quebec, Canada

Allan Blair Cancer Centre; 🇨🇦 Regina, Saskatchewan, Canada

CHUM - Centre Hospitalier de l'Universite de Montreal; 🇨🇦 Montreal, Quebec, Canada

Saskatoon Cancer Centre; 🇨🇦 Saskatoon, Saskatchewan, Canada

Ehime University Hospital; 🇯🇵 Toon, Ehime, Japan

Kure National Hospital; 🇯🇵 Kure, Hiroshima, Japan

Niigata University Medical and Dental Hospital; 🇯🇵 Niigata City, Niigata, Japan

Saitama Medical University International Medical Center; 🇯🇵 Saitama, Japan

Seoul National University Bundang Hospital; 🇰🇷 Seongnam City, Kyeonggi-do, Korea, Republic of

Samsung Changwon Hospital; 🇰🇷 Seoul, Gyeongsangnam-do, Korea, Republic of

Keimyung University-Dongsan Medical Center; 🇰🇷 Dalseo-gu, Daegu, Korea, Republic of

Kyungpook National University Chilgok Hospital; 🇰🇷 Daegu, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

Gangnam Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

Yonsei University Health System-Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

Korea Cancer Center Hospital; 🇰🇷 Seoul, Korea, Republic of

Centro Comprensivo de Cancer de UPR; 🇵🇷 San Juan, Puerto Rico

Cleveland Clinic Cancer Center/Fairview Hospital; 🇺🇸 Cleveland, Ohio, United States

UPMC-Magee Womens Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

West Penn Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

University of Pittsburgh Cancer Institute (UPCI); 🇺🇸 Pittsburgh, Pennsylvania, United States

Swedish Medical Center-First Hill; 🇺🇸 Seattle, Washington, United States

Ben Taub General Hospital; 🇺🇸 Houston, Texas, United States

Naval Medical Center -San Diego; 🇺🇸 San Diego, California, United States

University of Cincinnati Cancer Center-UC Medical Center; 🇺🇸 Cincinnati, Ohio, United States

Zuckerberg San Francisco General Hospital; 🇺🇸 San Francisco, California, United States

California Pacific Medical Center-Pacific Campus; 🇺🇸 San Francisco, California, United States

Kaiser Permanente-San Francisco; 🇺🇸 San Francisco, California, United States

Kaiser Permanente San Leandro; 🇺🇸 San Leandro, California, United States

Mercy Oncology Center; 🇺🇸 Redding, California, United States

Kaiser Permanente-Riverside; 🇺🇸 Riverside, California, United States

Kaiser Permanente-Roseville; 🇺🇸 Roseville, California, United States

University of Utah Sugarhouse Health Center; 🇺🇸 Salt Lake City, Utah, United States

Kaiser Permanente-San Diego Zion; 🇺🇸 San Diego, California, United States

Kaiser Permanente-Vallejo; 🇺🇸 Vallejo, California, United States

Kaiser Permanente-Walnut Creek; 🇺🇸 Walnut Creek, California, United States

John Muir Medical Center-Walnut Creek; 🇺🇸 Walnut Creek, California, United States

Northwestern Medicine Cancer Center Warrenville; 🇺🇸 Warrenville, Illinois, United States

The Community Hospital; 🇺🇸 Munster, Indiana, United States

Mount Sinai Hospital; 🇺🇸 New York, New York, United States

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Staten Island University Hospital; 🇺🇸 Staten Island, New York, United States

Westchester Medical Center; 🇺🇸 Valhalla, New York, United States

Highland Hospital; 🇺🇸 Rochester, New York, United States

Memorial Sloan Kettering Nassau; 🇺🇸 Uniondale, New York, United States

State University of New York Upstate Medical University; 🇺🇸 Syracuse, New York, United States

Southeastern Medical Oncology Center-Jacksonville; 🇺🇸 Jacksonville, North Carolina, United States

Vanderbilt University/Ingram Cancer Center; 🇺🇸 Nashville, Tennessee, United States

Case Western Reserve University; 🇺🇸 Cleveland, Ohio, United States

MetroHealth Medical Center; 🇺🇸 Cleveland, Ohio, United States

Good Samaritan Hospital - Cincinnati; 🇺🇸 Cincinnati, Ohio, United States

Geauga Hospital; 🇺🇸 Chardon, Ohio, United States

Summa Health System - Akron Campus; 🇺🇸 Akron, Ohio, United States

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States

Ohio State University Comprehensive Cancer Center; 🇺🇸 Columbus, Ohio, United States

Hillcrest Hospital Cancer Center; 🇺🇸 Mayfield Heights, Ohio, United States

UH Seidman Cancer Center at Lake Health Mentor Campus; 🇺🇸 Mentor, Ohio, United States

ProMedica Flower Hospital; 🇺🇸 Sylvania, Ohio, United States

University of Cincinnati Cancer Center-West Chester; 🇺🇸 West Chester, Ohio, United States

Ephrata Cancer Center; 🇺🇸 Ephrata, Pennsylvania, United States

Lehigh Valley Hospital-Cedar Crest; 🇺🇸 Allentown, Pennsylvania, United States

Geisinger Medical Center; 🇺🇸 Danville, Pennsylvania, United States

UPMC-Johnstown/John P. Murtha Regional Cancer Center; 🇺🇸 Johnstown, Pennsylvania, United States

Lancaster General Ann B Barshinger Cancer Institute; 🇺🇸 Lancaster, Pennsylvania, United States

Geisinger Cancer Services-Pottsville; 🇺🇸 Pottsville, Pennsylvania, United States

Wexford Health and Wellness Pavilion; 🇺🇸 Wexford, Pennsylvania, United States

Asplundh Cancer Pavilion; 🇺🇸 Willow Grove, Pennsylvania, United States

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center; 🇺🇸 Houston, Texas, United States

Methodist Willowbrook Hospital; 🇺🇸 Houston, Texas, United States

Houston Methodist Hospital; 🇺🇸 Houston, Texas, United States

Houston Methodist The Woodlands Hospital; 🇺🇸 The Woodlands, Texas, United States

University of Virginia Cancer Center; 🇺🇸 Charlottesville, Virginia, United States

MultiCare Gig Harbor Medical Park; 🇺🇸 Gig Harbor, Washington, United States

MultiCare Good Samaritan Hospital; 🇺🇸 Puyallup, Washington, United States

Kadlec Clinic Hematology and Oncology; 🇺🇸 Kennewick, Washington, United States

Valley Medical Center; 🇺🇸 Renton, Washington, United States

MultiCare Tacoma General Hospital; 🇺🇸 Tacoma, Washington, United States

Poudre Valley Hospital; 🇺🇸 Fort Collins, Colorado, United States

Memorial Hospital North; 🇺🇸 Colorado Springs, Colorado, United States

Essentia Health Cancer Center; 🇺🇸 Duluth, Minnesota, United States

University of Kansas Cancer Center; 🇺🇸 Kansas City, Kansas, United States

North Colorado Medical Center; 🇺🇸 Greeley, Colorado, United States

Penrose-Saint Francis Healthcare; 🇺🇸 Colorado Springs, Colorado, United States

University of Kansas Hospital-Indian Creek Campus; 🇺🇸 Overland Park, Kansas, United States

Sanford Broadway Medical Center; 🇺🇸 Fargo, North Dakota, United States

UCHealth Greeley Hospital; 🇺🇸 Greeley, Colorado, United States

McKee Medical Center; 🇺🇸 Loveland, Colorado, United States

Sanford Bismarck Medical Center; 🇺🇸 Bismarck, North Dakota, United States

Cancer Care and Hematology-Fort Collins; 🇺🇸 Fort Collins, Colorado, United States

University of Kansas Clinical Research Center; 🇺🇸 Fairway, Kansas, United States

Sanford Joe Lueken Cancer Center; 🇺🇸 Bemidji, Minnesota, United States

University of Rochester; 🇺🇸 Rochester, New York, United States

Baystate Medical Center; 🇺🇸 Springfield, Massachusetts, United States

University of Alabama at Birmingham Cancer Center; 🇺🇸 Birmingham, Alabama, United States

University of Oklahoma Health Sciences Center; 🇺🇸 Oklahoma City, Oklahoma, United States

Providence Saint Vincent Medical Center; 🇺🇸 Portland, Oregon, United States

Legacy Good Samaritan Hospital and Medical Center; 🇺🇸 Portland, Oregon, United States

Providence Portland Medical Center; 🇺🇸 Portland, Oregon, United States

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States

University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

CTCA at Western Regional Medical Center; 🇺🇸 Goodyear, Arizona, United States

Cedars Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro; 🇺🇸 Jonesboro, Arkansas, United States

Norwalk Hospital; 🇺🇸 Norwalk, Connecticut, United States

Saint Luke's Cancer Institute - Meridian; 🇺🇸 Meridian, Idaho, United States

Hartford Hospital; 🇺🇸 Hartford, Connecticut, United States

Florida Cancer Specialists - Venice Island; 🇺🇸 Venice, Florida, United States

Stamford Hospital/Bennett Cancer Center; 🇺🇸 Stamford, Connecticut, United States

Smilow Cancer Hospital-Torrington Care Center; 🇺🇸 Torrington, Connecticut, United States

Yale-New Haven Hospital North Haven Medical Center; 🇺🇸 North Haven, Connecticut, United States

Florida Cancer Specialists - Bradenton Cancer Center; 🇺🇸 Bradenton, Florida, United States

Danbury Hospital; 🇺🇸 Danbury, Connecticut, United States

The Hospital of Central Connecticut; 🇺🇸 New Britain, Connecticut, United States

Smilow Cancer Hospital Care Center-Trumbull; 🇺🇸 Trumbull, Connecticut, United States

Smilow Cancer Hospital Care Center - Guilford; 🇺🇸 Guilford, Connecticut, United States

Smilow Cancer Hospital Care Center at Saint Francis; 🇺🇸 Hartford, Connecticut, United States

Smilow Cancer Hospital Care Center - Waterford; 🇺🇸 Waterford, Connecticut, United States

MedStar Washington Hospital Center; 🇺🇸 Washington, District of Columbia, United States

Penobscot Bay Medical Center; 🇺🇸 Rockport, Maine, United States

MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford; 🇺🇸 Sanford, Maine, United States

Genesys Hurley Cancer Institute; 🇺🇸 Flint, Michigan, United States

Florida Cancer Specialists - Sarasota; 🇺🇸 Sarasota, Florida, United States

Florida Cancer Specialists - Sarasota Downtown; 🇺🇸 Sarasota, Florida, United States

Sarasota Memorial Hospital; 🇺🇸 Sarasota, Florida, United States

Saint Alphonsus Cancer Care Center-Caldwell; 🇺🇸 Caldwell, Idaho, United States

Our Lady of the Lake Medical Oncology; 🇺🇸 Baton Rouge, Louisiana, United States

Florida Cancer Specialists - Venice Healthpark; 🇺🇸 Venice, Florida, United States

Lafayette Family Cancer Center-EMMC; 🇺🇸 Brewer, Maine, United States

Saint Luke's Cancer Institute - Boise; 🇺🇸 Boise, Idaho, United States

Saint Alphonsus Cancer Care Center-Nampa; 🇺🇸 Nampa, Idaho, United States

University of Maryland/Greenebaum Cancer Center; 🇺🇸 Baltimore, Maryland, United States

Saint Agnes Hospital; 🇺🇸 Baltimore, Maryland, United States

Maine Medical Center- Scarborough Campus; 🇺🇸 Scarborough, Maine, United States

Lowell General Hospital; 🇺🇸 Lowell, Massachusetts, United States

Greater Baltimore Medical Center; 🇺🇸 Baltimore, Maryland, United States

Billings Clinic Cancer Center; 🇺🇸 Billings, Montana, United States

Genesee Hematology Oncology PC; 🇺🇸 Flint, Michigan, United States

University of Maryland Shore Medical Center at Easton; 🇺🇸 Easton, Maryland, United States

MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford; 🇺🇸 Biddeford, Maine, United States

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

MedStar Franklin Square Medical Center/Weinberg Cancer Institute; 🇺🇸 Baltimore, Maryland, United States

Winchester Hospital; 🇺🇸 Winchester, Massachusetts, United States

Saint Charles Health System; 🇺🇸 Bend, Oregon, United States

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center; 🇺🇸 Lebanon, New Hampshire, United States

Sparrow Hospital; 🇺🇸 Lansing, Michigan, United States

Monmouth Medical Center; 🇺🇸 Long Branch, New Jersey, United States

Saint Alphonsus Medical Center-Ontario; 🇺🇸 Ontario, Oregon, United States

CHI Health Saint Francis; 🇺🇸 Grand Island, Nebraska, United States

Memorial Sloan Kettering Monmouth; 🇺🇸 Middletown, New Jersey, United States

Mississippi Baptist Medical Center; 🇺🇸 Jackson, Mississippi, United States

West Michigan Cancer Center; 🇺🇸 Kalamazoo, Michigan, United States

Munson Medical Center; 🇺🇸 Traverse City, Michigan, United States

MD Anderson Cancer Center at Cooper-Voorhees; 🇺🇸 Voorhees, New Jersey, United States

Rutgers Cancer Institute of New Jersey; 🇺🇸 New Brunswick, New Jersey, United States

Cooper Hospital University Medical Center; 🇺🇸 Camden, New Jersey, United States

Community Hospital of Anaconda; 🇺🇸 Anaconda, Montana, United States

Valley Health System-Hematology/Oncology; 🇺🇸 Westwood, New Jersey, United States

Monmouth Medical Center Southern Campus; 🇺🇸 Lakewood, New Jersey, United States

Saint Barnabas Medical Center; 🇺🇸 Livingston, New Jersey, United States

Memorial Sloan Kettering Bergen; 🇺🇸 Montvale, New Jersey, United States

Jersey Shore Medical Center; 🇺🇸 Neptune, New Jersey, United States

Robert Wood Johnson University Hospital Somerset; 🇺🇸 Somerville, New Jersey, United States

The Valley Hospital-Luckow Pavilion; 🇺🇸 Paramus, New Jersey, United States

Odette Cancer Centre- Sunnybrook Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada

Baptist Memorial Hospital and Cancer Center-Memphis; 🇺🇸 Memphis, Tennessee, United States

Prisma Health Cancer Institute - Seneca; 🇺🇸 Seneca, South Carolina, United States

Rapid City Regional Hospital; 🇺🇸 Rapid City, South Dakota, United States

Lancaster General Hospital; 🇺🇸 Lancaster, Pennsylvania, United States

Huntsman Cancer Institute/University of Utah; 🇺🇸 Salt Lake City, Utah, United States

Saint Francis Hospital; 🇺🇸 Greenville, South Carolina, United States

Prisma Health Cancer Institute - Faris; 🇺🇸 Greenville, South Carolina, United States

Aurora Cancer Care-Racine; 🇺🇸 Racine, Wisconsin, United States

Saint Francis Cancer Center; 🇺🇸 Greenville, South Carolina, United States

Marshfield Clinic-Minocqua Center; 🇺🇸 Minocqua, Wisconsin, United States

Vince Lombardi Cancer Clinic-Sheboygan; 🇺🇸 Sheboygan, Wisconsin, United States

Aurora BayCare Medical Center; 🇺🇸 Green Bay, Wisconsin, United States

West Virginia University Healthcare; 🇺🇸 Morgantown, West Virginia, United States

Aurora Cancer Care-Southern Lakes VLCC; 🇺🇸 Burlington, Wisconsin, United States

Walter Reed National Military Medical Center; 🇺🇸 Bethesda, Maryland, United States

Nebraska Methodist Hospital; 🇺🇸 Omaha, Nebraska, United States

University of Nebraska Medical Center; 🇺🇸 Omaha, Nebraska, United States

Aurora Cancer Care-Milwaukee; 🇺🇸 Milwaukee, Wisconsin, United States

Aurora Saint Luke's Medical Center; 🇺🇸 Milwaukee, Wisconsin, United States

Aurora Sinai Medical Center; 🇺🇸 Milwaukee, Wisconsin, United States

Waldo County General Hospital; 🇺🇸 Belfast, Maine, United States

Mercy Cancer Center - Sacramento; 🇺🇸 Sacramento, California, United States

University of California Davis Comprehensive Cancer Center; 🇺🇸 Sacramento, California, United States

Kaiser Permanente Downtown Commons; 🇺🇸 Sacramento, California, United States

Saint Joseph Mercy Hospital; 🇺🇸 Ann Arbor, Michigan, United States

University of Michigan Comprehensive Cancer Center; 🇺🇸 Ann Arbor, Michigan, United States

Wake Forest University Health Sciences; 🇺🇸 Winston-Salem, North Carolina, United States

Yale University; 🇺🇸 New Haven, Connecticut, United States

Alaska Women's Cancer Care; 🇺🇸 Anchorage, Alaska, United States

Kaiser Permanente-Bellflower; 🇺🇸 Bellflower, California, United States

Kaiser Permanente-Baldwin Park; 🇺🇸 Baldwin Park, California, United States

City of Hope Comprehensive Cancer Center; 🇺🇸 Duarte, California, United States

Community Cancer Institute; 🇺🇸 Clovis, California, United States

Alta Bates Summit Medical Center-Herrick Campus; 🇺🇸 Berkeley, California, United States

Kaiser Permanente - Harbor City; 🇺🇸 Harbor City, California, United States

City of Hope Antelope Valley; 🇺🇸 Lancaster, California, United States

Los Angeles County-USC Medical Center; 🇺🇸 Los Angeles, California, United States

UC San Diego Moores Cancer Center; 🇺🇸 La Jolla, California, United States

UCLA / Jonsson Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

Kaiser Permanente-Oakland; 🇺🇸 Oakland, California, United States

Palo Alto Medical Foundation-Gynecologic Oncology; 🇺🇸 Mountain View, California, United States

Saint Joseph Hospital - Orange; 🇺🇸 Orange, California, United States

Eisenhower Medical Center; 🇺🇸 Rancho Mirage, California, United States

Mercy Regional Cancer Center; 🇺🇸 Redding, California, United States

UC Irvine Health/Chao Family Comprehensive Cancer Center; 🇺🇸 Orange, California, United States

UCSF Medical Center-Mission Bay; 🇺🇸 San Francisco, California, United States

Kaiser Permanente-Santa Teresa-San Jose; 🇺🇸 San Jose, California, United States

Kaiser Permanente-South San Francisco; 🇺🇸 South San Francisco, California, United States

Kaiser Permanente-San Marcos; 🇺🇸 San Marcos, California, United States

Kaiser Permanente Medical Center - Santa Clara; 🇺🇸 Santa Clara, California, United States

City of Hope South Pasadena; 🇺🇸 South Pasadena, California, United States

Palo Alto Medical Foundation-Sunnyvale; 🇺🇸 Sunnyvale, California, United States

City of Hope Upland; 🇺🇸 Upland, California, United States

Medical Center of the Rockies; 🇺🇸 Loveland, Colorado, United States

Helen F Graham Cancer Center; 🇺🇸 Newark, Delaware, United States

Smilow Cancer Hospital-Waterbury Care Center; 🇺🇸 Waterbury, Connecticut, United States

Sibley Memorial Hospital; 🇺🇸 Washington, District of Columbia, United States

Emory University Hospital Midtown; 🇺🇸 Atlanta, Georgia, United States

Piedmont Fayette Hospital; 🇺🇸 Fayetteville, Georgia, United States

WellStar Cobb Hospital; 🇺🇸 Austell, Georgia, United States

Northside Hospital; 🇺🇸 Atlanta, Georgia, United States

Northeast Georgia Medical Center-Gainesville; 🇺🇸 Gainesville, Georgia, United States

CTCA at Southeastern Regional Medical Center; 🇺🇸 Newnan, Georgia, United States

WellStar Health System Inc; 🇺🇸 Marietta, Georgia, United States

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler; 🇺🇸 Savannah, Georgia, United States

Memorial Health University Medical Center; 🇺🇸 Savannah, Georgia, United States

Wellstar Kennestone Hospital; 🇺🇸 Marietta, Georgia, United States

WellStar North Fulton Hospital; 🇺🇸 Roswell, Georgia, United States

WellStar Vinings Health Park; 🇺🇸 Smyrna, Georgia, United States

Saint Alphonsus Cancer Care Center-Boise; 🇺🇸 Boise, Idaho, United States

Saint Luke's Cancer Institute - Fruitland; 🇺🇸 Fruitland, Idaho, United States

Saint Luke's Cancer Institute - Nampa; 🇺🇸 Nampa, Idaho, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Saint Luke's Cancer Institute - Twin Falls; 🇺🇸 Twin Falls, Idaho, United States

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States

University of Illinois; 🇺🇸 Chicago, Illinois, United States

University of Chicago Comprehensive Cancer Center; 🇺🇸 Chicago, Illinois, United States

Carle at The Riverfront; 🇺🇸 Danville, Illinois, United States

Crossroads Cancer Center; 🇺🇸 Effingham, Illinois, United States

NorthShore University HealthSystem-Evanston Hospital; 🇺🇸 Evanston, Illinois, United States

Cancer Care Specialists of Illinois - Decatur; 🇺🇸 Decatur, Illinois, United States

NorthShore University HealthSystem-Highland Park Hospital; 🇺🇸 Highland Park, Illinois, United States

NorthShore University HealthSystem-Glenbrook Hospital; 🇺🇸 Glenview, Illinois, United States

Northwestern Medicine Cancer Center Delnor; 🇺🇸 Geneva, Illinois, United States

Ingalls Memorial Hospital; 🇺🇸 Harvey, Illinois, United States

Carle Physician Group-Mattoon/Charleston; 🇺🇸 Mattoon, Illinois, United States

UC Comprehensive Cancer Center at Silver Cross; 🇺🇸 New Lenox, Illinois, United States

Loyola University Medical Center; 🇺🇸 Maywood, Illinois, United States

Springfield Clinic; 🇺🇸 Springfield, Illinois, United States

Carle Cancer Center; 🇺🇸 Urbana, Illinois, United States

Midwestern Regional Medical Center; 🇺🇸 Zion, Illinois, United States

Northwest Cancer Center - Main Campus; 🇺🇸 Crown Point, Indiana, United States

Northwest Oncology LLC; 🇺🇸 Dyer, Indiana, United States

Community Cancer Center East; 🇺🇸 Indianapolis, Indiana, United States

Franciscan Health Indianapolis; 🇺🇸 Indianapolis, Indiana, United States

Indiana University/Melvin and Bren Simon Cancer Center; 🇺🇸 Indianapolis, Indiana, United States

Community Cancer Center South; 🇺🇸 Indianapolis, Indiana, United States

Community Cancer Center North; 🇺🇸 Indianapolis, Indiana, United States

Ascension Saint Vincent Indianapolis Hospital; 🇺🇸 Indianapolis, Indiana, United States

Franciscan Health Mooresville; 🇺🇸 Mooresville, Indiana, United States

Northwest Cancer Center - Valparaiso; 🇺🇸 Valparaiso, Indiana, United States

Saint Catherine Hospital; 🇺🇸 Indianapolis, Indiana, United States

University of Iowa/Holden Comprehensive Cancer Center; 🇺🇸 Iowa City, Iowa, United States

Saint Elizabeth Healthcare Edgewood; 🇺🇸 Edgewood, Kentucky, United States

University of Kansas Hospital-Westwood Cancer Center; 🇺🇸 Westwood, Kansas, United States

Our Lady of The Lake; 🇺🇸 Baton Rouge, Louisiana, United States

East Jefferson General Hospital; 🇺🇸 Metairie, Louisiana, United States

Woman's Hospital; 🇺🇸 Baton Rouge, Louisiana, United States

Our Lady of the Lake Physicians Group - Medical Oncology; 🇺🇸 Baton Rouge, Louisiana, United States

Harold Alfond Center for Cancer Care; 🇺🇸 Augusta, Maine, United States

Anne Arundel Medical Center; 🇺🇸 Annapolis, Maryland, United States

UM Upper Chesapeake Medical Center; 🇺🇸 Bel Air, Maryland, United States

Lahey Hospital and Medical Center; 🇺🇸 Burlington, Massachusetts, United States

Spectrum Health at Butterworth Campus; 🇺🇸 Grand Rapids, Michigan, United States

Bronson Methodist Hospital; 🇺🇸 Kalamazoo, Michigan, United States

Mercy Hospital Saint Louis; 🇺🇸 Saint Louis, Missouri, United States

University of Mississippi Medical Center; 🇺🇸 Jackson, Mississippi, United States

Memorial Sloan Kettering Basking Ridge; 🇺🇸 Basking Ridge, New Jersey, United States

Community Medical Center; 🇺🇸 Scranton, Pennsylvania, United States

Neurosurgeons of New Jersey-Ridgewood; 🇺🇸 Ridgewood, New Jersey, United States

Valley Hospital; 🇺🇸 Ridgewood, New Jersey, United States

Valley Medical Group - Wayne Multispecialty Practice; 🇺🇸 Wayne, New Jersey, United States

Island Gynecologic Oncology; 🇺🇸 Brightwaters, New York, United States

University of New Mexico Cancer Center; 🇺🇸 Albuquerque, New Mexico, United States

Southwest Gynecologic Oncology Associates Inc; 🇺🇸 Albuquerque, New Mexico, United States

Northwell Health Imbert Cancer Center; 🇺🇸 Bay Shore, New York, United States

New York-Presbyterian/Brooklyn Methodist Hospital; 🇺🇸 Brooklyn, New York, United States

Roswell Park Cancer Institute; 🇺🇸 Buffalo, New York, United States

Memorial Sloan Kettering Commack; 🇺🇸 Commack, New York, United States

Memorial Sloan Kettering Westchester; 🇺🇸 Harrison, New York, United States

Northwell Health/Center for Advanced Medicine; 🇺🇸 Lake Success, New York, United States

The New York Hospital Medical Center of Queens; 🇺🇸 Flushing, New York, United States

Mount Sinai Chelsea; 🇺🇸 New York, New York, United States

Long Island Jewish Medical Center; 🇺🇸 New Hyde Park, New York, United States

Laura and Isaac Perlmutter Cancer Center at NYU Langone; 🇺🇸 New York, New York, United States

NYU Winthrop Hospital; 🇺🇸 Mineola, New York, United States

Mercy Hospital Springfield; 🇺🇸 Springfield, Missouri, United States

Kaiser Permanente-Irvine; 🇺🇸 Irvine, California, United States

Genesee Cancer and Blood Disease Treatment Center; 🇺🇸 Flint, Michigan, United States

UCHealth Memorial Hospital Central; 🇺🇸 Colorado Springs, Colorado, United States

UMass Memorial Medical Center - Memorial Division; 🇺🇸 Worcester, Massachusetts, United States

LSU Health Baton Rouge-North Clinic; 🇺🇸 Baton Rouge, Louisiana, United States

University Medical Center New Orleans; 🇺🇸 New Orleans, Louisiana, United States

Ochsner Baptist Medical Center; 🇺🇸 New Orleans, Louisiana, United States

Ochsner Medical Center Jefferson; 🇺🇸 New Orleans, Louisiana, United States

Saint Luke's Hospital of Kansas City; 🇺🇸 Kansas City, Missouri, United States

UNC Lineberger Comprehensive Cancer Center; 🇺🇸 Chapel Hill, North Carolina, United States

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States

Virginia Commonwealth University/Massey Cancer Center; 🇺🇸 Richmond, Virginia, United States

Queen's Medical Center; 🇺🇸 Honolulu, Hawaii, United States

Montefiore Medical Center-Einstein Campus; 🇺🇸 Bronx, New York, United States

Montefiore Medical Center - Moses Campus; 🇺🇸 Bronx, New York, United States

Kapiolani Medical Center for Women and Children; 🇺🇸 Honolulu, Hawaii, United States

University of Wisconsin Carbone Cancer Center; 🇺🇸 Madison, Wisconsin, United States

Northwest Cancer Center - Hobart; 🇺🇸 Hobart, Indiana, United States

Women's Diagnostic Center - Munster; 🇺🇸 Munster, Indiana, United States

Saint Mary Medical Center; 🇺🇸 Hobart, Indiana, United States

University of Chicago Medicine-Orland Park; 🇺🇸 Orland Park, Illinois, United States